David Paul Morris | Bloomberg | Getty Images
Here’s how the company did:
- Earnings: $1.13 per share, adjusted, vs. $1.18 per share as expected by analysts, according to Refinitiv.
- Revenue: $10.51 billion, vs. $10.51 billion as expected by analysts, according to Refinitiv.
Oracle’s revenue increased 4% from a year earlier in the quarter, which ended Feb. 28, according to a statement. Net income declined 54% to $2.32 billion.
Net income dropped due to two investments. The company said profit was hurt by the tumbling share price of gene-sequencing company Oxford Nanopore and an operating loss at Arm server chip maker Ampere Computing, a private company.
“We remain confident that our investments in these two cutting-edge technology companies will deliver very strong returns for Oracle,” Oracle said.
The company’s short-term deferred revenue, at $7.87 billion, came in below the StreetAccount consensus of $8.01 billion.
In the quarter Oracle announced its intent to acquire Cerner, a developer of software for managing health records, for $28.3 billion in cash.
With respect to guidance, Oracle said it expects $1.35 to $1.39 in adjusted earnings per share and 3% to 5% revenue growth in the fiscal fourth quarter. Analysts polled by Refinitiv had been looking for $1.38 per share and $11.76 billion in revenue, which works out to 4.8% revenue growth. The guidance does not include contributions from Cerner, Safra Catz, Oracle’s CEO, said on a conference call with analysts.
Executives will discuss the results with analysts on a conference call starting at 5 p.m. ET.
Prior to the after-hours move, Oracle stock was down 12% so far in 2022. The S&P 500 index has dropped about 11% over the same period.
This is breaking news. Please check back for updates.
Read More: Oracle (ORCL) earnings Q3 2022